



# THE CHEMISTRY OF **SUSTAINED RELATIONSHIPS**

Annual Report 2018-19



“

# ENVIRONMENT SAFETY IS OUR PRIME MOTTO

”

## Forward-looking statements:

In this annual report, we have disclosed certain forward-looking information to enable investors to comprehend our prospects and take informed investment decisions. This report and other statements - written and oral - that we periodically make certain forward-looking statements that set out anticipated results based on the management's plans and assumptions. We have tried wherever possible to identify such statements by using words such as 'anticipates', 'estimates', 'expects', 'projects', 'intends', 'plans', 'believes', and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward-looking statements will be realised, although we believe we have been prudent in our assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers should bear this in mind. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.



# CONTENTS

## 01 Corporate Overview

Corporate Information	05
Corporate Identity	06
Geographical Presence	12
Research & Development	15
Key Performance Indicators	16
Financial Highlights	18
Awards and Accolades	20
Corporate Social Responsibility	21
Board of Directors and Leadership Team	22
Chairman's Letter	24

## 02 Statutory Report

Management Discussion and Analysis	26
Notice	30
Board's Report	38
Report on Corporate Governance	63

## 03 Financial Statements


### Standalone Financials

Independent Auditor's Report	79
Balance Sheet	87
Profit and Loss Statement	88
Cash Flow Statement	90
Notes to Financial Statement	92

### Consolidated Financials

Independent Auditor's Report	117
Consolidated Balance Sheet	123
Consolidated Statement of Profit and Loss	124
Consolidated Cash Flow Statement	126
Notes to Consolidated Financial Statement	128





While the world is challenged with multiple pharmaceutical requirements and healthcare concerns, we at Aarti Drugs strive to develop innovative pharmaceutical solutions to transform lives, communities and other essential understanding of the limitless possibilities to realise sustainable value.

We ensure that our innovative ideas are brought to life while manufacturing the best-in-class products to the market. We also aspire to be the leaders in the supply and production of bulk drugs in the near future along with providing customised solutions and services to the customers to meet their changing requirements. This strong determination and dedication have led us to expanding our production capabilities of various products under different therapies which include Antidiabetic, Antibiotic, Specialty Chemicals etc.

The key enablers of our business are trusted products built over three decades coupled with the best manufacturing practices and methods. This strong foundation has eventually given us the confidence and courage to aim high in our goal to emerge as a truly global company.

With consistent technology upgradation, high business ethics and morale and the development of new products, we aim to meet every customer requirement while also delivering on our promises to our stakeholders.

**The chemistry  
of sustained  
relationships**



# Corporate Information

## Chairman Emeritus

Shri Chandrakant V. Gogri

## Board of Directors

Shri Prakash M. Patil  
Chairman, Managing Director & Chief Executive Officer  
Shri Rashesh C. Gogri  
Managing Director  
Shri Harshit M. Savla  
Jt. Managing Director

## Whole-time Directors

Shri Harit P. Shah  
Shri Uday M. Patil

## Non-executive Director

Shri Rajendra V. Gogri

## Independent Director

Shri Ramdas M. Gandhi  
CA Bhavesh R. Vora  
CA Navin C. Shah  
Dr. Krishnacharya G. Akamanchi  
Dr. Vilas G. Gaikar  
CA Priti P. Savla

## Chief Financial Officer

Shri Adhish P. Patil

## Registered Office

Plot No. 198, M.I.D.C.,  
Tarapur, Village-Pamtermbhi,  
Dist. Palghar- 401 506, Maharashtra

## Corporate Identification Number

L37060MH1984PLC055433

## Company Secretary & Compliance Officer

CS Vibhav S. Ranade (till 27<sup>th</sup> March 2019)  
CS Rushikesh Deole (w.e.f 23<sup>rd</sup> April 2019)

## Statutory Auditors

**Kirtane & Pandit LLP**  
Chartered Accountants,  
H/16, Saraswat Colony,  
Sitladevi Temple Road, Mahim,  
Mumbai - 400016. India.  
Phone : +91-022-24444119 / 5, 24469713  
Fax : +91-022-24441147  
Email : kpcamumbai@kirtanepandit.com

## Registrar & Share Transfer Agent

Link Intime India Pvt. Ltd.  
C 101, 247 Park, L. B. S. Marg,  
Vikhroli (West), Mumbai - 400 083,  
Maharashtra

## Bankers

Union Bank of India  
Bank of Baroda  
State Bank of India  
Standard Chartered Bank  
DBS Bank India Limited  
IDBI Bank Limited  
Citi Bank N.A.  
The Hongkong and Shanghai Banking Corporation Limited  
Kotak Mahindra Bank Limited  
IndusInd Bank Limited  
The Saraswat Co-Operative Bank Limited  
The SVC Co-Operative Bank Limited

## Corporate Office

Mahendra Industrial Estate, Ground Floor, Plot No. 109-D,  
Road No. 29, Sion (E), Mumbai- 400 022, Maharashtra  
Visit us at [www.aartidrugs.co.in](http://www.aartidrugs.co.in)



# CORPORATE IDENTITY

Aarti Drugs Limited was established in the year 1984 and forms part of \$900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited. Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.



# THE CHEMISTRY OF SUSTAINED RELATIONSHIPS





Seek global market leadership



Focus on growth and development of the product



Continue to create winning culture, operating in highest standards of ethics and values with co-operation among competitors



Strive for excellence in customer service, quality and R&D

## Mission



## Vision

**We Shall Become The First Choice Vendor Of Bulk Drugs And Achieve A Leadership Position By:**



Assuring consistent quality and timely delivery at competitive price.



Providing customized solutions and service to meet changing requirements of customers.



Choose the best and the most flexible manufacturing practices and methods.



Adopt processes supported by proven technologies, which are cost effective and safe.



Aim at customer orientation through continuous technology upgrade, high business ethics and new product development.

# KEY FACTS



13

Manufacturing facilities



~38%

Export revenue



100+

Countries



2,480<sub>MT</sub>

Monthly API Capacity



1,452

Employees



50,983<sub>Sq.M</sub>

Plant Area



50+

API Molecules



80+

Finished Products





One of the leading producers of  
Metformin in the world

One of the Largest producer in  
Fluoroquinolones in the world

Largest producer of Tinidazole in the  
world

Largest producer of Metronidazole  
Benzoate in the world

Largest producer of Metronidazole in  
India

Largest producer of Ketoconazole in the  
world

Largest producer of Nimesulide in the  
world

*Disclaimer: Based on information available with the company*

# Milestones

